| Similar Articles |
|---|
 |
The Motley Fool
October 12, 2010
Brian Orelli |
This Drugmaker Stands on a Platform Above the Rest ImmunoGen signs up another partner.   |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
March 31, 2011
Brian Orelli |
Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles. |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
January 6, 2011
Brian Orelli |
$145 Million Down; Billions to Go Seattle Genetics signs up another partner. |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
The Motley Fool
August 31, 2010
Rich Duprey |
Why Did My Stock Just Die? These stocks just rolled over. Can they come back? |
The Motley Fool
July 13, 2011
Brian Orelli |
2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
The Motley Fool
July 15, 2011
Brian Orelli |
Seattle Genetics Will Work It Out This isn't the NFL labor negotiations. |
The Motley Fool
September 14, 2010
Brian Orelli |
This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key. |
The Motley Fool
August 20, 2011
Luke Timmerman |
Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas. |
The Motley Fool
August 31, 2011
Brian Orelli |
Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by. |
The Motley Fool
September 9, 2011
Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
The Motley Fool
June 21, 2011
Brian Orelli |
Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen. |
The Motley Fool
July 5, 2011
Luke Timmerman |
Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high. |
Chemistry World
June 12, 2012
Nina Notman |
Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
June 13, 2008
Brian Lawler |
Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval. |
The Motley Fool
August 22, 2011
Brian Orelli |
Speedy in Seattle Seattle Genetics gets an early approval of Adcentris. |
The Motley Fool
July 12, 2011
Luke Timmerman |
Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug. |
The Motley Fool
April 8, 2011
Brian Orelli |
A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
February 9, 2007
Brian Lawler |
Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing. |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
July 9, 2008
Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
The Motley Fool
July 14, 2011
Luke Timmerman |
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S. |
The Motley Fool
November 17, 2006
Brian Lawler |
Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note. |
BusinessWeek
September 5, 2005
Michael Arndt |
Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool
August 31, 2010
Brian Orelli |
A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus. |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
Bio-IT World
May 19, 2004
Barbara Depompa |
Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company. |
The Motley Fool
August 26, 2009
Brian Orelli |
This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
ifeminists
October 26, 2005
Wendy McElroy |
Miracle Cure, or Murky Research? Why does sloppy medical research succeed? That is, why is it accepted by the medical establishment, and then heralded by the press? Because big money and big reputations hang in the balance. The drug Herceptin may work for breast cancer, but it may not. When will we know the truth? |
